Valbiotis SA (FR:ALVAL) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Valbiotis SA, a French lab specializing in dietary supplements for metabolic and cardiovascular health, has been selected to present its Phase II/III clinical study results of TOTUM•63 at the prestigious EASD congress in 2024. The study showcases TOTUM•63’s effectiveness against prediabetes and type 2 diabetes, marking a significant innovation in non-drug treatments. Additionally, Valbiotis has begun preliminary discussions for international marketing partnerships.
For further insights into FR:ALVAL stock, check out TipRanks’ Stock Analysis page.